Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27635328 | 0.87 | PDK1 (0.44) | PDK1PDK2PDK3PDK4TOP2A | |
| SCHEMBL8359921 | 0.82 | TDP1 (0.50) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL20374364 | 0.81 | TDP1 (0.48) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL9153345 | 0.81 | TDP1 (0.48) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL12369337 | 0.79 | SIGMAR1 (0.48) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL13302606 | 0.79 | TDP1 (0.57) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL12674309 | 0.79 | NEK2 (0.43) | TDP1ALDH1A1TSHRL3MBTL1HSD17B10 | |
| SCHEMBL12871183 | 0.79 | NR1H4 (0.52) | TDP1ALDH1A1ENPP2 | |
| SCHEMBL15981420 | 0.79 | TDP1 (0.42) | TDP1ALDH1A1TSHRLMNAALOX12 | |
| SCHEMBL9313156 | 0.79 | TDP1 (0.67) | TDP1ALDH1A1TSHRLMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| CN-101784520-B | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-02 | — | — | CN | disclosed |
| US-8563588-B2 | Imidazolone derivatives, method for the preparation thereof and biological applications | UNIVERSITE DE RENNES 1 (FR) | 2013-10-22 | — | — | US | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100216855-A1 | IMIDAZAOLONE DERIVATIVES,PREPARATION THEREOF AND BIOLOGICAL USE OF SAME | UNIVERSITE DE RENNES (FR) | 2010-08-26 | — | — | US | disclosed |
| CN-101784520-A | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2010-07-21 | — | — | CN | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087063-A1 | IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216855-A1 | IMIDAZAOLONE DERIVATIVES,PREPARATION THEREOF AND BIOLOGICAL USE OF SAME | NR0B2, HRH1, HRH2 | TDP1 3808/4885PDK1 3026/4885PDK2 1630/4885 |
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | TDP1 1268/4885PDK1 1051/4885PDK2 1130/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | TDP1 1268/4885PDK1 1051/4885PDK2 1130/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | TDP1 1268/4885PDK1 1051/4885PDK2 1130/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | TDP1 4770/4885PDK1 289/4885PDK2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.